VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd-generation non-hallucinogenic psychedelic analogs for the treatment of neuropsychological disorders, is pleased to announce it has obtained positive results…

Source

Previous articlePT285 – Andrew Penn, NP – The Need for Nurses in Psychedelics, The Placebo Effect, and Appreciating the Subtle
Next articleRed Light Holland to Collaborate with Advocacy Group, Psychedelic Medicine Alliance Washington to Promote Proposed Psilocybin Legalization Bill in Washington State